Exelixis Advances Cancer Studies with Rising Analyst Confidence

Exelixis, Inc. (NASDAQ:EXEL) has gained analyst confidence with significant rises in price targets. The company advances its studies following the price target increases from Barclays and UBS. Exelixis focuses on discovering, developing, and commercializing oncology medicines, with key products CABOMETYX and COMETRIQ targeting difficult-to-treat cancers. The company's low volatility and potential EPS growth make it an attractive investment, although certain AI stocks offer greater upside potential and less downside risk.

Title: Analysts Boost Price Targets for Exelixis Inc., Reflecting Optimism in Oncology Focus

Exelixis Inc. (NASDAQ: EXEL) has seen a surge in analyst confidence, with several major firms raising their price targets on the biotechnology company. This positive outlook comes as the company continues to advance its studies in oncology, focusing on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers.

Key Highlights:

- Morgan Stanley: The firm raised its price target for Exelixis from $47.00 to $48.00, representing a 2.13% increase [2]. This adjustment reflects a positive outlook on the company's stock performance.

- UBS Group: UBS Group set a $43.00 target price for Exelixis, indicating a potential downside of 2.85% from the company's previous close [1].

- Royal Bank of Canada: The bank reaffirmed a "sector perform" rating and set a $50.00 price objective for Exelixis, up from $45.00 [1].

- JMP Securities: The firm increased its price objective on Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating [1].

- Jefferies Financial Group: Jefferies set a $50.00 price objective on Exelixis and gave the stock a "buy" rating [1].

- Stifel Nicolaus: The firm increased its price objective on Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating [1].

- Citigroup: Citigroup increased its target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating [1].

Market Performance:

Exelixis has a market capitalization of $12.07 billion, a PE ratio of 20.12, a P/E/G ratio of 0.89, and a beta of 0.28. The company's 50-day moving average price is $43.17, and its 200-day moving average price is $38.47. The stock opened at $44.26 on Friday, July 11, 2025.

Insider Activity:

CFO Christopher J. Senner sold 100,000 shares of the firm's stock on Friday, May 16, 2025, at an average price of $46.00, for a total transaction of $4,600,000.00. Following the transaction, the CFO owned 967,842 shares of the company's stock, valued at approximately $44,520,732. This trade represents a 9.36% decrease in their ownership of the stock [1].

Institutional Investor Activity:

Several hedge funds have recently made changes to their positions in Exelixis. Byrne Asset Management LLC boosted its holdings in Exelixis by 129.0% in the second quarter, now owning 710 shares valued at $31,000. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the fourth quarter, valued at $25,000. Hemington Wealth Management boosted its holdings by 211.3% in the first quarter, now owning 769 shares valued at $28,000 [1].

Conclusion:

The significant rise in price targets from various analyst firms indicates a growing optimism in Exelixis' ability to deliver strong returns. While the company's focus on oncology makes it an attractive investment, it is essential for investors to consider the potential risks and compare it with other AI stocks offering greater upside potential and less downside risk.

References:

[1] https://www.marketbeat.com/instant-alerts/exelixis-nasdaqexel-given-new-4300-price-target-at-ubs-group-2025-07-14/
[2] https://www.gurufocus.com/news/2993950/exelixis-exel-price-target-raised-by-morgan-stanley-exel-stock-news